14789
-
Clinical Ophthalmology
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Rituximab for refractory granulomatous eye disease
Case Series
(2660) Total Article Views
Authors: Lower EE, Baughman RP, Kaufman AH
Published Date October 2012 Volume 2012:6 Pages 1613 - 1618
DOI: http://dx.doi.org/10.2147/OPTH.S35521
| Received: | 01 July 2012  |
|---|---|
| Accepted: | 11 August 2012 |
| Published: | 05 October 2012 |
1Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA
Objective: To determine the effectiveness of rituximab therapy for patients with granulomatous disease of the eye.
Methods: Retrospective review was undertaken of cases seen at a single institution for ocular antineutrophil cytoplasmic antibody-associated vasculitis or sarcoidosis with persistent ocular disease despite systemic therapy. All patients were treated with rituximab and followed for at least 6 months.
Results: Nine patients were identified (five with antineutrophil cytoplasmic antibody-associated vasculitis, four with sarcoidosis), and all were treated for at least 6 months. Eight experienced improvement of eye disease and were able to reduce prednisone and other drug therapies. One patient remained stable, but still required high dosages of prednisone. All five patients with lung disease improved with rituximab therapy. Rituximab treatment was well tolerated. Two patients discontinued the drug due to leukopenia; however, both patients reinstituted rituximab at modified doses.
Conclusion: Rituximab therapy was effective in controlling granulomatous ocular disease in most cases. The drug was corticosteroid-sparing and effective in refractory cases, with no severe adverse events encountered.
Keywords: sarcoidosis, wegener’s, ANCA, cyclophosphamide
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Robert Baughman
Readers of this article also read:
- Interested in being a peer-reviewer?
Click here to register.
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, University of Texas Health Science Center, San Antonio.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Dexmedetomidine sedation in painful posterior segment surgery
